You are viewing an expired study

This study is not currently recruiting Study Participants on If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Iowa City, Iowa 52242

  • Lymphoma, Follicular


The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Follicular Lymphoma (FL).


Inclusion Criteria: - Relapsed or refractory follicular lymphoma grade I-II - Tumor verified to be CD20 positive - CT scan showing demarcated lesions Exclusion Criteria: - Previous treatment with rituximab resulting in less than partial response - Previous radioimmunotherapy - Previous stem cell transplantation - Received the following treatments within 4 weeks prior to entering this study: 1. Anti-cancer therapy 2. Glucocorticosteroids unless less than 10 mg prednisolone/day 3. Radiotherapy - Received Mitomycin C or Nitrosoureas within 6 weeks prior to entering this trial - HIV positivity - Hepatitis B or hepatitis C - Uncontrolled or chronic bacterial, fungal or viral infection - Other cancer diseases, except certain skin cancers, cervix cancer and breast cancer - Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, and stomach, lung, heart, hormonal, nerve or blood diseases - WHO performance status of 3 or 4 - If you are participating in another trial with a different new drug 4 weeks before you enter this trial - Current participation in any other clinical study - Pregnant or breast-feeding women - Women of childbearing age who are unable or unwilling to use an IUD or hormonal birth control during the whole trial



Primary Contact:


Backup Contact:


Location Contact:

Iowa City, Iowa 52242
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.